ARTICLE | Finance
The brig idea
Why Ariad opted for an Iclusig royalty deal with PDL
August 10, 2015 7:00 AM UTC
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) hopes monetizing its lone marketed drug via a royalty deal will allow it to get a second cancer compound across the finish line.
The prospect of selling stock to fund development of brigatinib (AP26113) was not appealing, as Ariad has seen its shares fall about 23% from their 52-week high of $9.89 in late April. ...